Key Performance Data Summary

OUR PEOPLE

2013/14 2014/15 2015/16

Total headcount

Number

13,468

14,874

17,021

For more information, please see our people

Lost time injury frequency rate (LTIFR)

Per million hours worked

1.43

0.75

1.04

Medical treatment injury frequency rate (MTIFR)

Per million hours worked

5.77

6.22

4.98

Days lost frequency rate (DLFR)

Per million hours worked

28.36

17.82

15.69

Serious injury/illness frequency rate (SIIFR)

Per million hours worked

0.52

0.24

0.27

INNOVATION

2013/14 2014/15 2015/16

R&D investment

US$million

466

463

614

For more information, please see innovation performance

SAFETY AND QUALITY

2013/14 2014/15 2015/16

Regulatory audits

Number

179

263

281

For more information, please see page safety performance

Quality audits of suppliers

Number

435

497

584

Safety related recalls of finished product

Number

2

3

3

ECONOMIC CONTRIBUTION

2013/14 2014/15 2015/16

Economic value generated

US$million

5,524

5,628

6,129

For more information, please see marketplace performance

Economic value distributed

US$million

4,956

5,009

6,098

COMMUNITY

2013/14 2014/15 2015/16*

Total contribution

US$million

32.8

28.4

29.6

For more information, please see community performance

ENVIRONMENT

2013/14 2014/15 2015/16

Energy consumption

Petajoules

2.25

2.43

2.87

In 2015/16, CSL increased its footprint from five to seven manufacturing sites following the acquisition of the Novartis influenza vaccine business. For comparative purposes, we have provided two years of historical data (2013/14 and 2014/15) which excludes the Novartis influenza vaccine acquired sites. For more information on our environmental performance, visit our website at www.csl.com.au/corporate-responsibility.htm

Greenhouse gas emissions

Metric Kilotonnes

223

240

303

Water consumption

Gigalitres

2.60

2.69

3.14

Waste

Metric Kilotonnes

20.26

21.83

44.07

Waste recycling rate

%

59

64

56

* Does not include data for the operations acquired from the Novartis influenza vaccine business.